Procter & Gamble Hygiene and Health Care reported a challenging second quarter with net profit declining 6.7% to ₹195.84 crore compared to ₹209.86 crore in the same quarter last year. According to the latest unaudited financial results approved by the board on November 12, 2026, the company's revenue from operations stood at ₹1,145 crore for Q2 FY27, representing a marginal 0.4% decline from last year's figure of ₹1,150.17 crore. The profit after tax of ₹195.84 crore was approximately 6.7% lower than Q2 FY26's ₹209.86 crore, with basic and diluted earnings per share at ₹60.33 each compared to ₹64.65 in the corresponding period last year. The EBITDA margin contracted to 22.7% from 24.8% in the year-ago period, indicating pressure on profitability despite revenue stability.
For the September quarter, the company's revenue from operations was ₹1,145 crore, showing sequential growth from ₹89,146 lakh in Q1 FY27 and representing a marginal 0.4% decline from last year's figure of ₹1,150.17 lakh. As reported by the latest financial disclosure, total income for Q2 FY27 was ₹1,16,209 lakh, including other income of ₹1,701 lakh, with profit before tax at ₹26,202 lakh. For the six months ended September 30, 2026, revenue from operations was ₹2,063 crore, representing a 2% decline from ₹2,077 crore in H1 FY26. The stock closed flat at ₹7,200 per share on the BSE on Thursday, reflecting investor concerns over the company's weak earnings performance despite the marginal revenue decline.
Management attributed the double-digit impact on profitability to commodity cost fluctuations, specifically rising raw material and energy costs, alongside unfavorable foreign exchange rates. According to the latest financial disclosure, a significant portion of this margin erosion was offset by the company's robust productivity program. The company continues to face headwinds from raw material costs and unfavorable FX rates, which have significantly impacted profitability despite the firm's strategic focus on maintaining operational efficiency. Total expenses increased to ₹900 crore in Q2 FY27, representing a 2.47% year-on-year increase, partly driven by increased advertising and sales promotion costs. For the six months ended September 30, 2026, total expenses stood at ₹1,63,133 lakh against ₹1,55,831 lakh in H1 FY26.
Despite the challenging financial performance, managing director Kumar Venkatasubramanian emphasized the company's strategic focus on brand investments and long-term competitiveness. According to the latest disclosure, the company continued to significantly invest back in innovation, and advertising and promotion in the September quarter to position itself for long-term competitiveness and value creation. Venkatasubramanian expressed confidence in the company's integrated growth strategy, highlighting their focus on daily use categories where performance drives brand choice and superiority, with significant investment in innovation and A&P continuing despite margin pressures. He added that the company's strategic priorities, combined with the strength of their brands and organizational capabilities, position them well to leverage future growth opportunities and create sustainable long-term value for stakeholders.
The company's total equity grew from ₹75,347 lakh at March 2026 to ₹88,409 lakh at September 2026, while cash and cash equivalents stood at ₹71,520 lakh at the close of the period. As per the latest financial disclosure, the results were subjected to a limited review by statutory auditors Kalyaniwalla & Mistry LLP, with no qualification from the auditors based on the review. The company confirmed it has no subsidiary, associate, or joint venture as of September 30, 2026, maintaining its standalone operations across health care products and hygiene products segments. PGHH, a listed entity of Procter & Gamble India, operates in the healthcare and feminine care segments with brands such as Vicks and Whisper in its portfolio.
